Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: Experience from an urban arthritis clinic

Adam Mor, Clifton Bingham, M. Kishimoto, P. M. Izmirly, J. D. Greenberg, S. Reddy, P. B. Rosenthal

Research output: Contribution to journalArticle

Abstract

Objectives: Reactivation of Mycobacterium tuberculosis (TB) is a significant problem with all available tumour necrosis factor (TNF) antagonists when used to treat rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and other inflammatory diseases. Concerns have been raised regarding the appropriate management of patients with latent TB (LTB) exposure (or active TB infection) before initiating TNF antagonists as the safety data of combined treatment with two potentially hepatotoxic medications, methotrexate (MTX) and isoniazid (INH), is lacking. The goal of this study was to investigate the toxicity of MTX and INH treatment in patients with RA before initiating TNF antagonists. Methods: To investigate the toxicity of MTX and INH treatment in patients with RA we performed a retrospective chart review of patients seen at the Bellevue Hospital Arthritis Clinic in New York City between 2002 and 2006. Forty-four patients who were concomitantly treated with both drugs were included. The primary outcome investigated was increase in liver function tests (LFT). Results: Transient increases in LFT were seen in 11% of patients, but in no case was this more than twice the upper limit of normal values. All abnormal LFT resolved spontaneously without intervention. In addition, no patient has developed signs or symptoms of TB reactivation. Conclusions: The use of INH for LTB was well tolerated in patients with RA on a background regimen of MTX. While the risks and benefits of all treatment must always be considered, in our experience the additive risk of INH to MTX in terms of hepatotoxicity was low. None the less it is prudent to follow LFT closely on patients taking this combination.

Original languageEnglish (US)
Pages (from-to)462-465
Number of pages4
JournalAnnals of the Rheumatic Diseases
Volume67
Issue number4
DOIs
StatePublished - Apr 2008

Fingerprint

Latent Tuberculosis
Isoniazid
Methotrexate
Arthritis
Rheumatoid Arthritis
Liver
Liver Function Tests
Tumor Necrosis Factor-alpha
Toxicity
Therapeutics
Tuberculosis
Psoriatic Arthritis
Mycobacterium tuberculosis
Psoriasis
Signs and Symptoms
Pharmaceutical Preparations
Reference Values
Safety

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis : Experience from an urban arthritis clinic. / Mor, Adam; Bingham, Clifton; Kishimoto, M.; Izmirly, P. M.; Greenberg, J. D.; Reddy, S.; Rosenthal, P. B.

In: Annals of the Rheumatic Diseases, Vol. 67, No. 4, 04.2008, p. 462-465.

Research output: Contribution to journalArticle

@article{b17e9f0ead0e44a999b2943f439d1c75,
title = "Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis: Experience from an urban arthritis clinic",
abstract = "Objectives: Reactivation of Mycobacterium tuberculosis (TB) is a significant problem with all available tumour necrosis factor (TNF) antagonists when used to treat rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and other inflammatory diseases. Concerns have been raised regarding the appropriate management of patients with latent TB (LTB) exposure (or active TB infection) before initiating TNF antagonists as the safety data of combined treatment with two potentially hepatotoxic medications, methotrexate (MTX) and isoniazid (INH), is lacking. The goal of this study was to investigate the toxicity of MTX and INH treatment in patients with RA before initiating TNF antagonists. Methods: To investigate the toxicity of MTX and INH treatment in patients with RA we performed a retrospective chart review of patients seen at the Bellevue Hospital Arthritis Clinic in New York City between 2002 and 2006. Forty-four patients who were concomitantly treated with both drugs were included. The primary outcome investigated was increase in liver function tests (LFT). Results: Transient increases in LFT were seen in 11{\%} of patients, but in no case was this more than twice the upper limit of normal values. All abnormal LFT resolved spontaneously without intervention. In addition, no patient has developed signs or symptoms of TB reactivation. Conclusions: The use of INH for LTB was well tolerated in patients with RA on a background regimen of MTX. While the risks and benefits of all treatment must always be considered, in our experience the additive risk of INH to MTX in terms of hepatotoxicity was low. None the less it is prudent to follow LFT closely on patients taking this combination.",
author = "Adam Mor and Clifton Bingham and M. Kishimoto and Izmirly, {P. M.} and Greenberg, {J. D.} and S. Reddy and Rosenthal, {P. B.}",
year = "2008",
month = "4",
doi = "10.1136/ard.2007.076406",
language = "English (US)",
volume = "67",
pages = "462--465",
journal = "Annals of the Rheumatic Diseases",
issn = "0003-4967",
publisher = "BMJ Publishing Group",
number = "4",

}

TY - JOUR

T1 - Methotrexate combined with isoniazid treatment for latent tuberculosis is well tolerated in patients with rheumatoid arthritis

T2 - Experience from an urban arthritis clinic

AU - Mor, Adam

AU - Bingham, Clifton

AU - Kishimoto, M.

AU - Izmirly, P. M.

AU - Greenberg, J. D.

AU - Reddy, S.

AU - Rosenthal, P. B.

PY - 2008/4

Y1 - 2008/4

N2 - Objectives: Reactivation of Mycobacterium tuberculosis (TB) is a significant problem with all available tumour necrosis factor (TNF) antagonists when used to treat rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and other inflammatory diseases. Concerns have been raised regarding the appropriate management of patients with latent TB (LTB) exposure (or active TB infection) before initiating TNF antagonists as the safety data of combined treatment with two potentially hepatotoxic medications, methotrexate (MTX) and isoniazid (INH), is lacking. The goal of this study was to investigate the toxicity of MTX and INH treatment in patients with RA before initiating TNF antagonists. Methods: To investigate the toxicity of MTX and INH treatment in patients with RA we performed a retrospective chart review of patients seen at the Bellevue Hospital Arthritis Clinic in New York City between 2002 and 2006. Forty-four patients who were concomitantly treated with both drugs were included. The primary outcome investigated was increase in liver function tests (LFT). Results: Transient increases in LFT were seen in 11% of patients, but in no case was this more than twice the upper limit of normal values. All abnormal LFT resolved spontaneously without intervention. In addition, no patient has developed signs or symptoms of TB reactivation. Conclusions: The use of INH for LTB was well tolerated in patients with RA on a background regimen of MTX. While the risks and benefits of all treatment must always be considered, in our experience the additive risk of INH to MTX in terms of hepatotoxicity was low. None the less it is prudent to follow LFT closely on patients taking this combination.

AB - Objectives: Reactivation of Mycobacterium tuberculosis (TB) is a significant problem with all available tumour necrosis factor (TNF) antagonists when used to treat rheumatoid arthritis (RA), psoriatic arthritis, psoriasis and other inflammatory diseases. Concerns have been raised regarding the appropriate management of patients with latent TB (LTB) exposure (or active TB infection) before initiating TNF antagonists as the safety data of combined treatment with two potentially hepatotoxic medications, methotrexate (MTX) and isoniazid (INH), is lacking. The goal of this study was to investigate the toxicity of MTX and INH treatment in patients with RA before initiating TNF antagonists. Methods: To investigate the toxicity of MTX and INH treatment in patients with RA we performed a retrospective chart review of patients seen at the Bellevue Hospital Arthritis Clinic in New York City between 2002 and 2006. Forty-four patients who were concomitantly treated with both drugs were included. The primary outcome investigated was increase in liver function tests (LFT). Results: Transient increases in LFT were seen in 11% of patients, but in no case was this more than twice the upper limit of normal values. All abnormal LFT resolved spontaneously without intervention. In addition, no patient has developed signs or symptoms of TB reactivation. Conclusions: The use of INH for LTB was well tolerated in patients with RA on a background regimen of MTX. While the risks and benefits of all treatment must always be considered, in our experience the additive risk of INH to MTX in terms of hepatotoxicity was low. None the less it is prudent to follow LFT closely on patients taking this combination.

UR - http://www.scopus.com/inward/record.url?scp=41849148671&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=41849148671&partnerID=8YFLogxK

U2 - 10.1136/ard.2007.076406

DO - 10.1136/ard.2007.076406

M3 - Article

C2 - 17711866

AN - SCOPUS:41849148671

VL - 67

SP - 462

EP - 465

JO - Annals of the Rheumatic Diseases

JF - Annals of the Rheumatic Diseases

SN - 0003-4967

IS - 4

ER -